Lonza Group
Logotype for Lonza Group AG

Lonza Group (LONN) investor relations material

Lonza Group Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Lonza Group AG
Jefferies Global Healthcare Conference summary18 Nov, 2026

Strategy and execution

  • Strategy centers on a pure-play, multi-modality CDMO model, investment in innovative modalities, resilient global infrastructure, disciplined capital allocation and profitable above-market growth.

  • A new operating model launched on April 1, 2025, organizing operations into Advanced Synthesis, Integrated Biologics and Specialized Modalities; management linked it to stronger execution and financial performance.

  • The CHI sale, signed in March 2026, is valued at CHF 1.6bn-CHF 1.7bn and expected to close by year-end 2026; portfolio exits establish a pure-play CDMO focus.

  • Net Promoter Score doubled among big pharma customers and improved 50% among small biotechs; 70% of new molecules are based on integrated services.

  • Management said it met its December 2024 commitments and met or raised its 2025 and 2026 outlooks during those years.

Market and growth model

  • The underlying market has grown 6%-7% over decades; selected faster-growing segments add 1%-2% and pharmaceutical outsourcing to CDMOs adds another 1%-2%, supporting an 8%-10% addressable-market growth estimate.

  • The differentiated operating model is expected to add 2%-3% growth above the market; average long-term top-line ambition is 10%-13%.

  • The organic growth model targets low-teens average organic CER sales growth, expanding margins and midterm core EBITDA margin in the high 30s; growth investment is mid-to-high teens as a percentage of sales.

  • Since 2024, profitability increased by 4 percentage points over two years; management said growth accelerated to a 16%-17% CAGR, with ROIC and cash generation also rising.

  • Long-term ROIC ambition is 2-3x WACC; management described a progressive trajectory as the growth model rolls forward with increasing profitability.

Capacity and differentiated services

  • Active CapEx portfolio comprises 25 global projects worth CHF 8bn, with 90% directed to commercial mixed assets; expected peak ROIC is 30%-40%.

  • Services span eight modalities, product life cycles from preclinical to commercial, and scales from lab to large-scale manufacturing, addressing clients’ manufacturability needs.

  • The GS cell-line system has supported more than 100 drugs brought to market; the DNA-to-IND timeline is now six months.

  • ADC capacity investment continues in Visp, including a recently announced payload-linker project; management said capacity is available while additions are made to support growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Lonza Group earnings date

Logotype for Lonza Group AG
H2 202627 Jan, 2027
Lonza Group
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Lonza Group earnings date

Logotype for Lonza Group AG
H2 202627 Jan, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Lonza Group AG offers contract development and manufacturing services to the pharmaceutical, biotechnology, and specialty ingredients markets. The company supports drug production across biologics, small molecules, and cell and gene therapy, along with nutrition and personal care ingredients. It operates manufacturing and research facilities globally. The company is headquartered in Basel, Switzerland, and its shares are listed on the SIX.